-2016 total CF product revenues of $1.68 billion compared to $982 million in 2015; $980 million for ORKAMBI and $703 million for KALYDECO-
-Fourth-quarter 2016 total CF product revenues of $454 million; $277 million for ORKAMBI and $177 million for KALYDECO-
-Company reiterates 2017 financial guidance for ORKAMBI product revenues of $1.1 to $1.3 billion and KALYDECO product revenues of $690 to $710 million-
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full-year and quarter-ended December 31, 2016. On January 8, 2017, Vertex provided a comprehensive update on its ongoing research and development programs in cystic fibrosis (CF). The company today provided an update on its non-CF pipeline. Vertex also reiterated its financial guidance provided on January 8, 2017 for total 2017 ORKAMBI® (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) revenues and combined Non-GAAP R&D and SG&A expenses. Key financial results include:
For full article, please click here.
